Nail involvement is frequent in people with psoriasis. It can considerably impair health-related quality of life (HRQoL) beyond the impairments due to other psoriasis symptoms, for example, because patients feel ashamed of visible nail defects or because of the functional impairment in manual activities and walking. In clinical trials on nail psoriasis, it is therefore crucial to assess whether the treatment reduces HRQoL impairments that are specific to nail psoriasis. For this purpose, two validated patient questionnaires are available, the Nail Psoriasis Quality of Life Scale (NPQ10) and the Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL). The ten-item NPQ10 has the advantage of being short and thus quick to administer. The 20-item NAPPA-QOL, in contrast, assesses the different dimensions of HRQoL which is considered a multi-dimensional construct. Yet most randomized controlled trials on nail psoriasis do not evaluate HRQoL improvement. If they do, a number of different instruments are used, most of which are not nail specific. This makes comparison of trial outcomes difficult. Harmonizing the measurement of HRQoL in future clinical trials on nail psoriasis would improve comparability across studies and would also enhance the reliability of meta-analyses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566428 | PMC |
http://dx.doi.org/10.1007/s40257-021-00622-7 | DOI Listing |
J Multidiscip Healthc
December 2024
Rheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal.
Purpose: Psoriatic arthritis (PsA) and psoriasis (Pso) are highly heterogeneous inflammatory diseases. Multidisciplinary approaches are associated with improved results in both musculoskeletal (MSK) and skin manifestations. We describe the experience and main diagnostic and therapeutic outcomes of one of the largest and longest-running Rheumatology/Dermatology multidisciplinary PsA Clinic.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO Institute, Milan, Italy.
Objectives: The study aims to evaluate the applicability of the D2T psoriatic arthritis (PsA) definition, adapted from rheumatoid arthritis, within a single-center observational cohort of PsA patients treated with b/tsDMARDs. In addition, we aimed to establish a numerical index defining D2T-PsA based on the ratio of observed to expected failed b/tsDMARDs and to develop a predictive model identifying features associated with the D2T condition.
Methods: The study included 267 consecutive adult PsA patients receiving b/tsDMARDs, collecting demographic, clinical, and clinimetric data.
Front Immunol
December 2024
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Psoriatic arthritis (PsA) affects approximately one in five individuals with psoriasis. Early identification of patients with psoriasis at risk of developing PsA is crucial to prevent poor prognosis. We established a derivation cohort comprising 1,661 patients with psoriasis from 49 hospitals.
View Article and Find Full Text PDFFront Immunol
December 2024
Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
Introduction: Fungi, including , may be a trigger or exacerbate psoriasis, especially in difficult to treat (DTT) areas, through the activation of IL-17/23 axis.
Methods: In this study, seventy patients with DDT psoriasis were enrolled to evaluate species and/or other opportunistic fungi colonization rate at baseline (T0) and the impact of apremilast on fungal load, clinical outcome, serum cytokine levels and biochemical serum profile of patients after 16, 24 and 52 weeks of treatment.
Results: In our population, 33 (47%) patients were colonized by spp.
Clin Dermatol
December 2024
Department of Dermatology, Yale School of Medicine, New Haven, CT; Program in Translational Biomedicine, Yale University, New Haven, CT.
Dr. Irwin M. Braverman is recognized as an expert on many skin diseases including psoriasis, an immune-mediated disorder that presents with scaly erythematous plaques.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!